


**Product Name** : Ixazomib  
**Cat. No.** : PC-42596  
**CAS No.** : 1072833-77-2  
**Molecular Formula** : C<sub>14</sub>H<sub>19</sub>BCl<sub>2</sub>N<sub>2</sub>O<sub>4</sub>  
**Molecular Weight** : 361.0287  
**Target** : Proteasome  
**Solubility** : DMSO: ≥ 28 mg/mL



### Biological Activity

Ixazomib (MLN2238) is a potent, selective, orally bioavailable **proteasome** inhibitor with IC<sub>50</sub> of 3.4 nM. Ixazomib binds to and inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with K<sub>i</sub> of 0.93 nM, weakly inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC<sub>50</sub> of 31 and 3,500 nM). Ixazomib inhibits growth and induces apoptosis in MM cells. Ixazomib shows improved antitumor activity in models of lymphoma compared with bortezomib.

### References

Kupperman E, et al. **Cancer Res.** 2010 Mar 1;70(5):1970-80.  
Chauhan D, et al. **Clin Cancer Res.** 2011 Aug 15;17(16):5311-21.  
Lee EC, et al. **Clin Cancer Res.** 2011 Dec 1;17(23):7313-23.  
Tian Z, et al. **Blood.** 2012 Nov 8;120(19):3958-67.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com